Theories and new therapeutics to cure Alzheimer's disease;Nuevos conceptos y nuevos abordajes terapeuticos, fundamentos para combatir la enfermedad de Alzheimer

Anales de la Real Academia de Farmacia

Volumn 62, Issue 4, 1996, Pages 717-765

  Toledano, Adolfo ^a  

^a INSTITUTO CAJAL   (Spain)

Author keywords

'cholinergic drugs'; Alzheimer's disease; growth factors; tacrin

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ASCORBIC ACID; BRAIN DERIVED GROWTH FACTOR; CALCIUM ANTAGONIST; CHOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DIHYDROERGOCRISTINE; DIHYDROERGOTOXINE; GANGLIOSIDE; GINKGO BILOBA EXTRACT; GROWTH FACTOR; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROTROPHIN; NICARDIPINE; NIMODIPINE; NOOTROPIC AGENT; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; PIRACETAM; PYRITINOL; TACRINE; TENILSETAM; UNINDEXED DRUG; VASODILATOR AGENT; VELNACRINE; VINCAMINE;

AGED; ALZHEIMER DISEASE; HUMAN; LIVER TOXICITY; REVIEW;

EID: 0030440743     PISSN: None     EISSN: 1697428X     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Toledano, A. (1988). Hypotesis concerning the aetiology of Alzheimer's disease. Pharmacopsychiatry, 21: 17-25.
2. Cajal, S. Ramón y (1909-1911). Histologie de l'homme et des vértebrés. Maloine. Paris.
3. Toledano, A.; Díaz, M.G.; Alvarez, I. (1996). La comunicación celular base del funcionamiento del SNC. An. Real Acad. Farm. (este volumen).
4. Toledano, A. (1996). Teorias etiológicas y etiopatogénicas sobre la enfermedad de Alzheimer. An. Real Acad. Farm, (este volumen).
5. Alzheimer, A. (1907). Über eine eigenartige Erkrankung der Hirnrinde. Allg. Ztschr. Psychiat. 64: 146-148
6. Perry, E.K.; Johnson, M.; Kerwin, J.M.; Piggott, M.A.; Court, J.A.; Shaw, P. J; et al. (1992). Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol. Aging, 13: 393-400.
7. Bartus, R.T.; Dean R.L.; Beer, B.; Lippa, A.S. (1982). The cholinergic hypotesis of geriatric memory dysfunction. Science, 217: 408-417.
8. Beyreuther, K.; Masters, C.L. (1991). Amyloid precursor protein (APP) and beta-A4 amyloid in the etiology of Alzehimer's disease: precursor-product relationships in the derangement of neuronal function. Brain Pathol. 1: 241-251
9. Castaño, E.M.; Frangione, B. (1991). Alzheimer's disease from the perspective of the systemic and localized forms of amiloidosis. Brain Pathol. 1: 263-271.
10. Henderson, A.S. (1994). Epidemiology of the mental disorders. Dementia. OMS. Ginebra.
11. OMS. (1994). CIE-10. Trastornos mentales y del comportamiento. descripciones clínicas y pautas para el diagnóstico. Meditor, Madrid.
12. Khachaturian, Z. (1992). The five five, ten ten program to defeat Alzheimer's disease. Neurobiol. Aging, 13: 197-198.
13. Schaättlz, H.M. (1995) Neurotrophic factors: ready to go?. Trends Neurosci. 18: 463-464
14. Hammang, J.P.; Emerich, D.F.; Winn, S.R.; Lee, A.; Lindner, M.D.; Gentile, F.T.; Doherty, E.J.; Kordower, J.H.; Baetge, E.E. (1995). Delivery of neurotrophic factors to the CNS using encapsulated cells: developing treatments for neurodegenerative diseases. Cell. Transplant. 1: S27-S28.
15. Wisniewski, H.M.; Kozlowski, P.B. (1982). Evidence for blood-brain-barrier changes in senile dementia of the Alzheimer type (SDAT). Ann. N. Y. Acad. Sci. 396: 119-129.
16. Probst, A.; Langui, D.; Ulrich, J. (1991). Alzheimer's disease: a descrption of the structural lesions. Brain Pathol. 1: 229-239.
17. Bascá L. (1994). Transducción de señales y mensajeros intracelulares. En: Cascales M, Villanueva JR (eds). Proliferación celular y cancer. Madrid, Real Academia de Farmacia/Fundación Científica de la Asociación Espańola contra el Cancer, 123-147.
18. Cross, M.; Dexter, T.M. (1991). Growth factors in development, transformation and tumorigenesis. Cell, 64: 271-280.
19. Martín-Zanca, D. (1994). Factores de crecimiento, receptores y oncogenes. En: Cascales M, Villanueva JR (eds). Proliferación celular y cancer. Madrid, Real Academia de Farmacia/Fundación Científica de la Asociación Española contra el Cancer, 39-121.
20. Coyle, J.T.; Price, D.L.; Delong, M.R. (1993). Alzheimer's disease: a disorder of cortical cholinergic innervation. Science, 219: 1184-1190.
21. Wenk, G.L.; Markowska, A.L.; Olton D.S. (1989). Basal forebrain lesions and memory: alterations in neurotensin, not acetylcholine, may cause amnesia. Behav. Neurosci. 103: 765-769.
22. Govoni, S.; Di Giovine, S.; Battani, F.; Trabuch, M. (1986). Age-releated changes in neurotensin content and receptors in various rat brain areas. Exp. Aging. Res. 12: 197-201.
23. Pepeu, G.; Pepeu, I.M. (1994). Dysfunction of the brain cholinergic system during aging and after lesions of the nucleus basalis of Meynert. J. Neural. Transm. [sup.] 44: 189-194.
24. Björklund, A.; Dunnett, S.B. (1995). Acetylcholine revisited. Nature. 375: 446.
25. Fibiger, H.C. (1991). Cholinergic mechanisms in learning memory and dementia: a review of recent evidence. Trends Neurosci. 14: 220-223.
26. Haroutunian, V.; Davis, K.L.; Davis, B.M.; Horvath, P.P.; Johns, C.A.; Morhs, R.C. (1985). The study of cholinomimetics in Alzheimer's disease and animal models. En: Iversen, SD (ed.). Psychopharmacology: recent advances and future prospects. Oxford University Press, Oxford, 218-259.
27. Maltby, N.; Broe, G.A.; Creasey, H.; Jorm, A.F.; Christensen, H.; Brooks, W.S. (1994). Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial. Brit. Med. J. 308: 879-883.
28. Cowburn, R.F. (1995). Membrane alterations in Alzheimer's disease and aging. Trends Neurosci. 18: 483-484.
29. Harrington, H.C.; Louwagie, J.; Rossau, R.; Vanmechelen, E.; Perry, R.H.; Perry, E.K.; Xuereb, J.H.; Roth, M.; Wischik, C.M. (1994). Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body type. Significance for etiological theories of Alzheimer's disease. Am. J. Pathol. 145: 1472-1482.
30. Murai, S.; Saito, H.; Abe, E.; Masuda, Y.; Odashima, J.; Itoh, T. (1994). MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice. J. Neural. Transm. [Gen. Sect.] 98: 1-13.
31. Pintor, A.; Fortuna, S.; Michalek, H. (1994). Carbachol-induced accumulation of inositol phosphates and its modulation by excitatory amino acids in cortical slices of young and aged rats with down-regulation of muscarinic M-1 recepetors. Neurochem. Res. 19: 1311-1317.
32. Cereda, E.; Brambilla, A.; Ezhaya, A.; Gaida, W.; Mendia, K.; Monferini, E.; Pitsikas, N.; Schiavi, G.B.; Sagrada, A. (1994). Medicinal chemistry of muscarinic agonist for the treatment of dementia disorders. Eur. J. Drug. Metab. Pharmacokinet. 19: 179-183.
33. Wanibuchi, F.; Nishida, T.; Yamachita, H.; Hidaka, K.; Koshiya, K.; Tsukamoto, S.; Usuda, S. (1994). Characterization of a novel muscarinic receptor agonist, YM796: comparision with cholinesterase inhibitors in vivo pharmacological studies. Eur. J. Pharmacol. 265: 151-158.
34. Quirion, R.; Wilson, A.; Rowe, W.; Aubert, I.; Richard, J.; Doods, H.; Parent, A.; White, N.; Meaney, M.J. (1995). Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired. J. Neurosci. 15: 1455-1462.
35. Dunbar, Pg.; Durant, G.J.; Rho, T.; Ojo, B.; Huzl, J.J.-3rd.; Smith, D.A.; elAssadi, A.A.; Sbeih, S.; Ngur, D.O.; Periyasamy, S.; et al. (1994). Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3, 4, 5, 6-tetrahydropyridines and 2-amino-5- (alkoxycarbonil)-1,4,5,6-tetrahydropyrimides as M1 muscarinic receptor agonist. J. Med. Chem. 37: 2774-2782.
36. Warpman, U.; Nordberg, A. (1995). Epibatidine and ABT 418 reveral selective losses of α4β2 nicotinic receptors in Alzheimer brains. Neuroreport. 6: 2419-2423.
37. James, J.R.; Nordberg, A. (1995). Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. Behav. Genet. 25: 149-159.
38. Wilson, A.L.; Langley, L.K.; Monley, J.; Bauer, T.; Rottunda, S.; McFalls, E.; Kovera, C.; McCarten, J.R. (1995). Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol. Biochem. Behav. 51: 509-514.
39. Arendash, G.W.; Sengstock, G.J.; Sanberg, P.R.; Kem, W.R. (1995) Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain. Res. 674: 252-259.
40. Mohr, E.; Feldman, H.; Gauthier, S. (1995). Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can. J. Neurol. Sci. 22: 62-71.
41. Hakansson, L. (1993). Mechanism of action of cholinesterase inhibitors in Alzheimer's disease. Acta. Neurol. Scand. Suppl. 149: 7-9.
42. Riekkinen, P.Jr.; Soininen, H.; Helkala, E.L.; Partanen, K.; Laakso, M.; Vanhanen, M.; Riekkinen, P. (1995). Hippocampal atrophy, acute THA treatment and memory in Alzheimer's disease. Neuroreport. 6: 1297-1300.
43. Neary, J.T.; Rathbone, M.P.; Cattabeni, F.; Abbracchio, M.P.; Burnstock, G. (1996). Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci. 19: 13-18.
44. Holford, N.H.; Peace, K. (1994). The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials. Eur. J. Clin. Pharmacol.47: 17-23.
45. Mohr, K.; Trankle, C. (1994). Allosteric effects of the alkane-bis-ammonium compound W84 and of tacrine on [3H]pirenzepine binding at M1-receptors in rat cerebral cortex. Pharmacol. Toxicol. 75: 391-394.
46. Lahiri, D.K. (1994). Reversibility of the effect of tacrine on the secretion of the beta-amyloid precursor protein in cultured cells. Neurosci. Lett. 181: 149-152.
47. Minthon, L.; Edvinsson, L.; Gustafson, L. (1994). Tacrine treatment modifies cerebrospinal fluid neuropeptide levels in Alzheimer's disease. Dementia. 5: 295-301.
48. Vivas, N.M.; Marmot, F.; Badia, A.; Dierssen, M. (1993). Differential effects of physostigmine and THA on β-adrenoceptor transduction system. Eur. J. Pharmacol. 245: 9-13.
49. Woo, J.K.; Lantz, M.S. (1995). Alzheimer's disease: how to give and monitor tacrine therapy. Geriatrics. 50: 50-53.
50. Antuono, P.G. (1995). Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane study group. Arch. Intern. Med. 155: 1766-1772.
51. Villalobos, A.; Butler, T.W.; Chapin, D.S.; Chen, Y.L.; De Mattos, S.B.; Ives, J.L.; Jones, S.B.; Liston, D.R.; Nagel, A.A.; Nason, D.M.; et al. (1995). 5,7-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl] ethyl]-6H-pyrrolo [3,2-1 ]-1,2-benzisoxazol-6-one: a potent and centrally-selective inhibitor of acetylcholinesterase with an improved margin of safety. J. Med. Chem. 38: 2802-2808.
52. Watkins, P.B.; Zimmerman, H.J.; Knapp, M.J.; Lewis, K.W. (1994). Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 271: 992-998.
53. Adem, A.; Mohammed, A.M.; Winblad, B.; Henriksson, B.E. (1994). A novel anticholinesterase THB 013: biochemical and behavioural studies. J. Neural. Transm. Park. Dis. Dement. 8: 139-148.
54. Franco-Maside, A.; Caamaño, J.; Gómez, M.J.; Cacabelos, R. (1994). Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease. Methods. Find. Exp. Clin. Pharmacol. 16: 597-607.
55. Linday, R.M. (1994). Neurotrophic growth factors and neurodegenerative diseases: therapeutic potencial of the neurotophins and ciliary neurotrophic factor. Neurobiol. Aging. 15: 149-251.
56. Fusca, M.; Vantini, G.; Schiavo, N.; Zanoni, R.; Facci, L.; Skaper, S.D. (1993). Gangliosides and neurotrophic factors in neurodegenerative diseases: from experimental findings to clinical perspectives. Ann. N. Y. Acad. Sci. 695: 314-317.
57. Rylett, R.J.; Willians, L.R. (1994). Role of neurotrophins in cholinergic - neurone function in the adult and aged CNS. Trends. Neurosci. 17: 486-490.
58. Butcher, L.L.; Wolf, N.J. (1989). Neurotrophic agents may exacerbate the pathologic cascade of Alzheimer's disease. Neurobiol. Aging. 10: 557-570.
59. Schätzl, H.M. (1995). Neurotrophic factor: ready to go?. Trends Neurosci. 18: 463-464.
60. Olson, L.; Backman, L.; Ebendal, T.; Eriksdotter-Jonhangen, M.; Hoffer, B.; Humpel, C.; Freedman, R.; Giacobini, M.; Meyerson, B.; Nordberg, A.; et al. (1994). Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. J. Neurol. 242: S12-S15.
61. 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in and Alzheimer patient. J. Neural Transm. [Park. Demen. Sect] 4: 79-95.
62. Calamandrei, G.; Alleva, E. (1995). Neuronal growth factors, neurotrophins and memory deficiency. Behav. Brain Res. 66: 129-132.
63. Casamenti, F.; Scali, C.; Giovannelli, L.; Faussone-Pellegrini, M.S.; Pepeu, G. (1994). Effect of nerve growth factor and GM1 ganglioside on the recovery of cholinergic neurons after a lesions of the nucleus basalis in aging rats. J. Neural. Transm. 7: 177-193.
64. Leeden, R.W. (1984). Biology of gangliosides: neuritogenic and neuronotrophic properties. J. Neurosci. Res. 12: 147-159.
65. Rahmann, H. (1995). Brain gangliosides and memory formation. Behav. Brain Res. 66: 105-116.
66. Valsecchi, M.; Palestini, P.; Chigarno, V.; Sonnino, S. (1996). Age-related changes of the ganglioside long-chain base composition in rat cerebellum. Neurochem. Int. 28: 183-187.
67. Svennerholm, L. (1994). Gangliosides- a new therapeutic agent aginst stroke and Alzheimer's disease. Life. Sci. 55: 2125-2134.
68. Lauder, J.M. (1993). Neurotransmitters as growth regulatory signals: role of receptors and second mensengers. Trends Neurosci. 16: 233-239.
69. Coull, J.T. (1994). Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition. Drugs. Aging. 5: 116-126.
70. Gillis, J.C.; Benefield, P.; McTavish, D. (1994). Idebenone. A review of its pharmacodynamic and pharmacokinetic propeties, and therapeutic use in age-related cognitive disorders. Drugs. Aging. 5: 133-152.
71. Bergamasco, B.; Scarzella, L.; La-Commare, P. (1994). Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct. Neurol. 9: 161-168.
72. Mons, N.; Cooper, D.M.E. (1995). Adenylate cyclases: critical foci in neuronal signaling. Trends Neurosci. 18: 536-541.
73. Toledano, A.; Rodríguez-Arellano J.J.; Gómez de Segura, I.A.; de Miguel, E.; Martínez-Rodríguez, R. (1996). Bowel resection and neurotensin treatment. Histochemical study of neurotensin-like and somatostatin-like immunoreactivities and receptor. Cell. Molec. Biol. (en prensa).
74. Sato, H, Ota, Z.; Ogawa, N. (1991). Somatostatin receptors in the senecent rat brain: a quantitative autoradiographic study. Regul. Peptides.33: 81-92.
75. Unger, J.W.; Mc Neill, T.H.; Lapham, L.L.; Hamill, R.W. (1988). Neuropeptides and neuropathology of the amygdala in Alzheimer's disease: relationship between somatostatin, neuropeptide Y and subregional distribution of neuritic plaques. Brain Res. 248: 293-302.
76. Sofroniew, M.W. (1983). Vasopressin and oxytocin in mammalian brain and spinal cord. Trends. Neurosci. 6: 467-472.
77. Wierda, M.; Goudsmit, E.; Van-Der-Woude, P.F.; Pruba, J.S.; Horman, M.A.; Bogte, H.; Swaab, D.F. (1991). Oxytocin cell number in the human paraventricular nucleus remains constant with aging and in Alzheimer's disease. Neurobiol. Aging, 12: 511-516.
78. Murphy, S.; Simmons, M.L.; Agullo, L.; García, A.; Feinstein, D.L.; Galea, E. (1993). Synthesis of nitric oxide in CNS glial cells. Trends Neurosci. 16: 323-328.
79. Castro-Alamancos, M.A.; Arevalo, M.A.; Torres-Aleman, I. (1996). Involvement of protein kinase C and nitric oxide in the modulation by insulin-like growth factor-I of glutamate-induced gaba release in the cerebellum. Neurosci. 70: 843-847.
80. Michel, P.P.; Agid, Y. (1995). Death of septal cholinergic neurons produced by chronic exposure to glutamate is prevented by the noncompetitive NMDA receptor/channel antagonist, MK-801: role of nerve growth factor and nitric oxide. J. Neurosci. Res. 40: 764-775.
81. Martin, J.B. (1995). Gene therapy and pharmacological treatment of inherited neurological disordes. Trends. Biotechnol. 13: 28-35.
82. Jinnah, H.A.; Friedmann, T. (1995). Gene therapy and the brain. Br. Med. Bull. 51: 138-148.
83. Franklin, R.J.M.; Blakemore, W.F. (1995). Glial-cell transplantation and plasticity in the O-2A linkage-implications for CNS repair. Trends Neurosci. 18: 151-156.
84. Rothwell, N.J.; Hopkins, S.J. (1995). Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci. 18: 130-136.
85. o ed. Barcelona, Masson-Salvat Medicine 109-522.
86. Mondadori, C. (1994). In search of the mechanism of action of the nootropics: new insights and potential clinical implications. Life Sci. 55: 2171-2178.
87. Pepeu, G.; Spignoli, G. (1989). Nootropic drugs and brain cholinergic mechanisms. Prog. Neuropsychopharmacol. Biol. Psychiatry 13: 577-588
88. Stoll, L.; Schubert, T.; Müller, W.E. (1991). Age-related deficits of central muscarinic cholinergic recptor function in the mouse: partial restoration by chronic piracetam treatment. Neurobiol. Aging. 13: 39-44.
89. Lopes da Silva, S.; Burbach, J.P.H. (1995). The nuclear hormone-receptor family in the brain: classics and orphans. Trends Neurosci. 18: 542-548.
90. Toledano, A.; Bentura, M.L. (1994). Pyritinol facilitates the recovery of cortical cholinergic deficits caused by nucleus basalis lesions. J. Neural Trans. [Park. Demen. Sect.] 7: 195-209
91. Toledano, A. (1992). Impairment of the cholinergic system of the nucleus basalis. En: Maurer K (ed.). Dementias: Neurochemistry, neuropathology, neuroimaging, neuropsychology, genetics. Vieweg, Berlin, 1-24
92. Herrmann, W.M.; Kern, U.; Röhmel, J. (1986) On the effects of pyritinol on functional defecits of patients with organic mental disorders. Pharmacopsychiatry 19: 378-385
93. Vermon, M.W.; Sorkin, E.M. (1991). Piracetam: an overview of its pharmacological properties and a review of its therapeutic use in senile cognition disorders. Drugs. Aging. 1: 17-35.
94. Lee, C.R.; Benfield, P. (1994). Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders. Drugs. Aging. 4: 257-273.
95. Miquel, J. (1991). An Integrated theory of aging as the result of mitochondrial-ADN mutation on differentiated cells. Arch. Gereontol. Geriratr. 12: 99-117.
96. Smith, M.A.; Sayre, L.M.; Manmer, V.; Perry, G. (1995). Radical ageing in Alzheimer's disease. Trends Neurosci. 18: 172-176.
97. Toledano, A. (1993). Mitochondria, brain aging and degenerative disorders. Aging. Clin. Exp. Res. 5: 459-461.
98. Mattson, M.P. (1992). Calcium as sculptor and destroyer of neural circuitry. Exp. Gerontol. 27: 29-49.
99. 2+ -binding proteins in human neurodegenerative disorders. Trends Neurosci. 15: 259-264.
100. Levere, T.E.; Walker, A. (1991). Old age and cognition: enhancement of recent memory in aged rats by the calcium channel blocker nimodipine. Neurobiol. Aging. 13: 63-66.
101. Barthel, F.; Boutillier, A.L.; Trouslard, J.; Loeffler, J.Ph. (1996). Fine tuning of calcium entry into neurons regulates adenosine 3′,5′-monophosphate-dependent transcription by several distinct mechanisms. Neuroscience, 70: 1053-1065.
102. Cooper, D.M.F.; Mons, N.; Karpen, J.W. (1995). Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature, 374: 421-424.
103. Emre, M.; Geula, C.; Ransil, B.J.; Mesulam, M.M. (1992). The acute neurotixicity and effects upon cholinergic axons of intracerebrally injected β-amyloid in the rat brain. Neurobiol. Aging. 13: 553-559.
104. Barger, S.W.; Fiscus, R.R.; Ruth, P.; Hormann, F.; Mattson, M.P. (1995). Role of cyclic GMP in the regulation of neuronal calcium and survival by secreted forms of beta-amyloid precursor. J. Neurochem. 64: 2087-2096.
105. Dresse, A.; Marechal, D.; Scuvee-Moreau, J.; Seutin, V. (1994). Towards a pharmacological approach of Alzheimer's disease based on the molecular biology of amyloid precursor protein (APP). Life Sci. 55: 2179-2187.
106. Muir, J.L.; Everitt, B.J.; Robbins, T.W. (1994). AMPA-induced excitoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function. J. Neurosci. 14: 2313-2326.
107. Coyle, J.T.; Puttfarcken, P. (1993). Oxidative stress, glutamate and neurodegenerative disorders. Science, 262: 689-700.
108. Wu, J.; Anwyl, R.; Rowan, M.J. (1995). β amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport, 6: 2409-2413.
109. Schneider, L.S.; Tariot, P.N. (1994). Emerging drugs for Alzheimer's disease. Mechanisms of action and prospects for cognitive enhancing medications. Med. Clin. North. Am. 78: 911-934.
110. Munch, G.; Taneli, Y.; Scharaven, E.; Schindler, U.; Schinzel, R.; Palm, D.; Riederer, P. (1994). The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J. Neural. Transm. [Park. Dement. Sect.] 8: 193-208.
111. Shem, J.G.; Zhou, D.Y. (1995). Efficiency of ginkgo biloba extract (EGb 761) in antioxidant protection against myocardial ischemia and reperfusion injury. Biochem. Mol. Biol. Int. 35: 125-134.
112. Miquel, J.; Ferrandiz, M.L.; De-Juan, E.; Sevilla, I.; Martínez, M. (1995). N-acetylcysteine protects against age-related decline of oxidative phosphorylation in liver mitochondria. Eur. J. Pharmacol. 292: 333-335.
113. Watanabe, T.; Yuki, S.; Egawa, M.; Nishi, H. (1994). Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J. Pharmacol. Exp. Ther. 268: 1597-1604.
114. Bregman, B.S.; Kunkel-Bagden, E.; Schenll, L.; Dai, H.N.; Gao, D.; Schwab, M.E. (1995). Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature, 378: 498-501.
115. Metsis, M.; Timmusk, T.; Allikmets, R.; Saorma, M.; Parsson, H. (1992). Regulatory elements and transcriptional regulation by testosterone and retinoic acid of the rat nerve growth factor receptor promoter. Gene, 121: 247-254.
116. Raff, M.C.; Barres, B.A.; Buine, J.F.; Coles, H.S.; Ishizaki, Y.; Jacobson, M.D. (1993). Programmed cell death and the control of cell survival: lesson from the nervous system. Science, 262: 695-700.
117. Tueth, M.J. (1995). How to manage depression and psychosis in Alzheimer's diasease. Geriatrics. 50: 43-46, 49.
118. Teri, L. (1994). Behavioral treatment of depression in patients with dementia. Alzheimer. Dis. Assoc. Disord. 8 (sup.) 3: 66-74.
119. Sky, A.J.; Grossberg, G.T. (1994). The use of psychotropic medication in the management of problem behaviours in the patient with Alzheimer's disease. Med, Clin. North. Am. 78: 811-822.
120. OMS. (1996) (en prensa). CIE-10. Trastornos mentales y del comportamiento. Version para Atención Primaria. Meditor, Madrid.
121. Decker, M.W.; Brioni, J.D.; Sullivan, J.P.; Buckley, M.J.; Raszkiewicz, J.L.; Kang, C.H.; Kim, D.J.; Giardina, W.J. Wasicak, J.T.; et al. (1994). (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic antivities: II. In vivo characterization. J. Pharmacol. Exp. Ther. 270: 319-328.
122. Carlyle, W.; Ancill, R.J.; Sheldon, L. (1993). Aggression in the demented patient: a double blind study of loxapine versus haloperidol. Int. Clin. Psychopharmacol. 8: 103-108.
123. Brooks, J.O.3rd.; Yesavage, J.A. (1995). Identification of fast and slow decliners in Alzheimer disease: a different approach. Alzheimer. Dis. Assoc Disord. 9 (sup. 1): S19-S25.
124. Emerich, D.F.; Winn, S.P.; Harper, J.; Hammang, J.P.; Baetge, E.E., Kordower, J.H. (1994). Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J. Comp. Neurol. 349: 148-164.
125. Olson, L. (1993). Reparative stragies in the brain: treatment strategies based on throphic factors and cell transfer techniques. Acta. Neurochir. Sup. 58: 3-7.
126. Olson, L. (1993). NGF and the treatment of Alzheimer's disease. Exp. Neurol. 124: 5-15.
127. Baetge, E.E. (1993). Neural stem cells for CNS transplantation. Ann. N. Y. Acad. Sci. 695: 285-291.
128. Gerdner, L.A. Swanson, E.A. (1993). Effects of individualized music on confused and agitated patients. Arch. Psychiatr. Nurs. 7: 284-291.
129. Scherder, E.J.; Bouma, A.; Steen, A.M. (1995). Effects of short-term transcutaneous electrial nerve stimulation on memory and affective behaviour in patients with probable Alzheimer's disease. Behav. Brain. Res. 67: 211-219.
130. Hefti, F. (1994). Neurotrophic factor therapy for nervous system degenerative diseases. J. Neurobiol. 25: 1418-1435.
131. Parker L.S. (1995). Ethical concerns in the research and treatment of complex disease. Trends Genet. 11:520-523.